Zeteo Biomedical receives new EU and US patents for its drug delivery technologies

News
Article

ZTech-L and ZTech-P, as part of the ZTech portfolio, supports administering therapeutics in both liquid and dry powder formulations

Microscopist working with biological samples in the microscope of the microbiology laboratory / Biochemical Engineer analyzing a sample on the microscope slide (Image credit: ©angellodeco/AdobeStock)

(Image credit: ©angellodeco/AdobeStock)

Zeteo Biomedical recently received new patents for its drug delivery technologies ZTech portfolio in both the United States and European Union.1 The first patent is titled, “Cartridge Devices for Administration of a Medicament” (US Patent No. 12329949), and the second patent is titled, “Hand-Operated Device for Administration of a Medicament” (EU Patent No. 3946526).

The patents allow Zeteo to further expand and strengthen its ZTech drug delivery platform portfolio, advancing the technologies of ZTech-L and ZTech-P, both of which include single-use disposable and multi-dose, cartridge-reloadable handheld devices.

“We are seeing increasing global demand for metered-dose nasal, ophthalmic and sublingual delivery devices that are compact, intuitive and suitable for self-administration,” said Timothy Sullivan, chief executive officer of Zeteo Biomedical.

“A unique feature that sets our device technology apart is its ability to function reliably in any physical orientation, making it ideal for medication delivery in both terrestrial and space-based microgravity environments. This capability opens exciting new frontiers for Zeteo including applications in space-based healthcare.”

The technologies of ZTech-L and ZTech-P support administering therapeutics in both liquid and dry powder formulations, including vaccines, biologics and specialty drugs. Zeteo noted in a press release that nasal delivery is particularly a highly effective, non-invasive alternative for the treatment of conditions like pain, emesis, seizures, neurodegenerative and autoimmune disorders, infectious diseases and bioterror threats.

Based in Texas, Zeteo’s platform technologies aim to meet the ever-evolving demands of healthcare markets globally, “delivering precision, performance, and portability for the next-generation of therapeutic drug/device combination products,” a press release said. Zeteo’s technology focuses on patient-friendly design, which can improve treatment adherence and medical outcomes.

Reference:
1. Sullivan T. Zeteo Biomedical Secures Global Patents for Nasal and Ophthalmic Drug Delivery Device Innovations. Zeteo Biomedical. Published June 11, 2025. Accessed June 11, 2025. https://zeteobiomed.com/2025/06/zeteo-biomedical-secures-global-patents-for-nasal-and-ophthalmic-drug-delivery-device-innovations/

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.